NPAU), an emerging biotech company, is pleased to announce the formation of its Next Generation Psychedelic Research Advisory Board and appointment of highly experienced Ms. Hattie Wells as its first member.
Hattie Wells brings over 20 years of experience working with psychedelic molecules and the therapeutic benefits they confer to individuals suffering from mental health and polysubstance abuse disorders. She holds an M.Sc. in Ethnobotany from the University of Kent, and B.Sc. in Social Anthropology from The London School of Economics, London, UK.
Ms. Wells’ research has been published by MAPS (the Multidisciplinary Association for Psychedelic Studies), and she serves as Co-Director of Breaking Convention, Europe’s largest conference on psychedelic consciousness. Ms. Wells has worked for a variety of NGOs including Amnesty International, Transform Drug Policy Foundation, The International Center for Ethnobotanical Education, Research, and Service (ICEERS), the Global Diversit
While many 2020 memories will be gladly left behind, that s not necessarily the case for psychedelics.
There was unprecedented renaissance as psychedelic compounds, and their potential to treat mental health conditions, became one of the centerpieces of this year’s public conversation.
Psychedelic companies those researching and producing these compounds jumped into the spotlight of investment markets, with almost two dozen psychedelics companies going public between February and December.
A public, institutional and financial interest in psychedelics ushered in a series of regulatory and legislative measures that opened the floodgates to levels of research never before seen in the space.
The impressive amount of news related to this sector also prompted Benzinga to launch Psyched, a weekly column on psychedelics which has already reached 30 issues and thousands of readers.
Psilocybin 2 0: Why Do We Have Reason to Believe? psychologytoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychologytoday.com Daily Mail and Mail on Sunday newspapers.
DEA Hit With Another Lawsuit From Scientists Seeking to Research Cannabis
DEA Hit With Another Lawsuit From Scientists Seeking to Research Cannabis
The time is nigh for the DEA to cooperate in ensuring that medical marijuana research can move forward. Finally.
On December 3, 2020, MAPS (the Multidisciplinary Association for Psychedelic Studies) issued a press release regarding a lawsuit filed against the DEA and the Attorney General to “compel issuance of licenses to manufacture marijuana for clinical trials and potential FDA approval.” We have written about MAPS and its 35 years of advocacy and engagement with DEA before, and we are big fans of the nonprofit.
Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets
Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets
MIAMI, Dec. 16, 2020 Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced KetaDASH www.ketadash.com, an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine.
Ehave, Inc. has entered into an asset purchase agreement to acquire the tangible and intangible assets of a San Diego, CA based IV therapy service CureDash www.curedash.com. CureDash currently operates an IV delivery platform that will become the backbone of KetaDash. KetaDASH will provide the platform for medical practitioners to administer Ketamine intravenously to patients at home. Ketamine is currently used to help ease pain and allows sedatives to be effective at lower doses, lessening the a